Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Achieving improvements in survival and reducing relapse remains a challenge in acute myelogenous leukemia (AML) patients. This study evaluated the in vitro efficacy of the active form of novel agent sapacitabine, CNDAC, compared to current chemotherapeutic drugs Ara-C and mitoxantrone using two AML...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagan, Sucheta, Paganessi, Laura A., Frank, Robin R., Venugopal, Parameswaran, Larson, Melissa, Christopherson, Kent W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461608/
https://www.ncbi.nlm.nih.gov/pubmed/23049558
http://dx.doi.org/10.1155/2012/727683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461608/
https://www.ncbi.nlm.nih.gov/pubmed/23049558
http://dx.doi.org/10.1155/2012/727683

Ejemplares similares